AptaBio

AptaBio Therapeutics is a Korean biopharmaceutical company founded in 2009, specializing in platform-based First-in-Class drug development for intractable diseases including diabetic complications, vascular disease, neurodegenerative disorders, and cancer. The company's core platforms target oxidative stress regulation (inflammation and fibrosis) and cancer-associated fibroblast (CAF) modulation to develop novel therapeutics with improved efficacy and reduced resistance. AptaBio is publicly listed on the Korean stock exchange and holds multiple patents in blood, pancreatic, and liver cancer therapies.